Beierlein W, Scheule A M, Antoniadis G, Braun C, Schosser R
Division of Thoracic, Cardiac and Vascular Surgery, Department of Surgery, Tübingen University Hospital, Tübingen Germany.
Transfusion. 2000 Mar;40(3):302-5. doi: 10.1046/j.1537-2995.2000.40030302.x.
The safety of fibrin tissue adhesives has been a concern since they entered wide clinical application. Most commercially available kits contain the proteolytic inhibitor, aprotinin, to stabilize the fibrin clot. A bovine protein, this substance has an allergenic potency.
This case report presents a patient who had a generalized allergic skin reaction, probably triggered by aprotinin upon reexposure to fibrin sealant injected subgaleally to achieve closure of a liquor fistula after neurosurgical treatment. The serologic investigation revealed aprotinin-specific IgE and IgG. From 1990 through 1998, reports of five allergic reactions following 1 million exposures to fibrin sealant were made to the manufacturer. The clinical relevance of allergic reactions to aprotinin contained in fibrin sealants and measures to avoid them are discussed.
These hypersensitivity reactions are extremely rare (incidence, 0.5/100,000 for all reactions and 0.3/100,000 for serious reactions), but they must be kept in mind as possible adverse events after repeated applications of fibrin sealants within a few weeks.
自纤维蛋白组织粘合剂广泛应用于临床以来,其安全性一直备受关注。大多数市售套件都含有蛋白水解抑制剂抑肽酶,以稳定纤维蛋白凝块。这种物质是一种牛蛋白,具有致敏性。
本病例报告介绍了一名患者,在神经外科治疗后,为封闭脑脊液瘘而在帽状腱膜下注射纤维蛋白封闭剂,再次接触抑肽酶后可能引发全身性过敏性皮肤反应。血清学调查显示存在抑肽酶特异性IgE和IgG。1990年至1998年期间,制造商收到了100万次纤维蛋白封闭剂暴露后发生5起过敏反应的报告。讨论了对纤维蛋白封闭剂中所含抑肽酶过敏反应的临床相关性及避免措施。
这些超敏反应极为罕见(所有反应的发生率为0.5/100,000,严重反应的发生率为0.3/100,000),但在几周内重复使用纤维蛋白封闭剂后,必须将其作为可能的不良事件加以考虑。